These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 28359815

  • 1. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H, Liu M, Yu A, Ji J, Zhai G.
    Int J Pharm; 2017 May 15; 523(1):427-438. PubMed ID: 28359815
    [Abstract] [Full Text] [Related]

  • 2. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O, Tang Y, Ke X, Chen Y, Hu D, Tu J, Zhao L, Bourkaib N.
    Int J Pharm; 2015 Jan 30; 478(2):553-68. PubMed ID: 25455765
    [Abstract] [Full Text] [Related]

  • 3. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
    Wang X, Gu X, Wang H, Yang J, Mao S.
    Carbohydr Polym; 2018 Sep 01; 195():170-179. PubMed ID: 29804965
    [Abstract] [Full Text] [Related]

  • 4. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW, Yu HY, Guo H, Lou J, Wang ZM, Liu P, Sapin-Minet A, Maincent P, Hong XC, Hu XM, Xiao YL.
    Mol Pharm; 2015 Mar 02; 12(3):675-83. PubMed ID: 25584860
    [Abstract] [Full Text] [Related]

  • 5. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Xia Y, Zhong J, Zhao M, Tang Y, Han N, Hua L, Xu T, Wang C, Zhu B.
    Drug Deliv; 2019 Dec 02; 26(1):1-11. PubMed ID: 31928356
    [Abstract] [Full Text] [Related]

  • 6. Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy.
    Wang FZ, Xing L, Tang ZH, Lu JJ, Cui PF, Qiao JB, Jiang L, Jiang HL, Zong L.
    Mol Pharm; 2016 Apr 04; 13(4):1298-307. PubMed ID: 26894988
    [Abstract] [Full Text] [Related]

  • 7. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
    Liu Y, Zhou Z, Lin X, Xiong X, Zhou R, Zhou M, Huang Y.
    Biomacromolecules; 2019 Oct 14; 20(10):3755-3766. PubMed ID: 31465208
    [Abstract] [Full Text] [Related]

  • 8. Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin.
    Xiong H, Ni J, Jiang Z, Tian F, Zhou J, Yao J.
    Biomater Sci; 2018 Aug 21; 6(9):2527-2540. PubMed ID: 30105340
    [Abstract] [Full Text] [Related]

  • 9. Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride.
    Zhang B, Yang X, Wang Y, Zhai G.
    Mater Sci Eng C Mater Biol Appl; 2017 Jun 01; 75():198-206. PubMed ID: 28415455
    [Abstract] [Full Text] [Related]

  • 10. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
    Xie X, Li F, Zhang H, Lu Y, Lian S, Lin H, Gao Y, Jia L.
    Eur J Pharm Sci; 2016 Feb 15; 83():28-35. PubMed ID: 26690044
    [Abstract] [Full Text] [Related]

  • 11. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T, Lan Y, Cao M, Ma X, Cao A, Sun Y, Yang J, Li L, Liu Y.
    Colloids Surf B Biointerfaces; 2019 Mar 01; 175():106-115. PubMed ID: 30529816
    [Abstract] [Full Text] [Related]

  • 12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F, Zhong Z.
    J Control Release; 2015 May 10; 205():144-54. PubMed ID: 25596560
    [Abstract] [Full Text] [Related]

  • 13. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
    Chen F, Zhang J, He Y, Fang X, Wang Y, Chen M.
    Biomater Sci; 2016 Jan 10; 4(1):167-82. PubMed ID: 26484363
    [Abstract] [Full Text] [Related]

  • 14. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
    Huang W, Lang Y, Hakeem A, Lei Y, Gan L, Yang X.
    Int J Nanomedicine; 2018 Jan 10; 13():1723-1736. PubMed ID: 29606866
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y, Su Z, Xue L, Xu H, Zhang C.
    J Control Release; 2016 May 10; 229():80-92. PubMed ID: 26945977
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
    Guo H, Zhang D, Li T, Li C, Guo Y, Liu G, Hao L, Shen J, Qi L, Liu X, Luan J, Zhang Q.
    J Pharm Sci; 2014 Mar 10; 103(3):987-93. PubMed ID: 24549734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.